MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
Key Details
- 1Proton therapy controls leptomeningeal metastasis, with patients living over twice as long versus conventional radiation.
- 2Randomized phase 2 trial: proton craniospinal therapy offers stability >3x longer for LM compared to standard radiation.
- 3Study funded by PCORI explores LLM-based PainReporter model to summarize cancer patient pain experiences from narrative notes.
- 4Research on tumor genetics and location finds SMAD4 reactivation suppresses liver metastases but increases lung metastases.
- 5Regulatory T cells, via enkephalin, regulate pain/inflammation in skin neuronal circuits.
Why It Matters
Advances in radiotherapeutic options like proton therapy improve outcomes in difficult cancer metastasis scenarios. Testing LLMs for summarising patient pain could impact clinical workflow, interpretation, and the integration of AI into patient care.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Enhanced Imaging Breaks Barriers in Complex Media for Biomedical Use
Researchers developed a physics-based machine learning imaging system that enhances visibility through complex media, holding promise for biomedical imaging.